Geron Corp. (GERN)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Geron Corp. (GERN)
Go deeper and ask any question about GERN
Company Performance
Current Price
as of Sep 13, 2024$4.51
P/E Ratio
N/A
Market Cap
$2.72B
Description
Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.
Metrics
Overview
- HQFoster City, CA
- SectorHealth Technology
- IndustryBiotechnology
- TickerGERN
- Price$4.51+1.35%
Trading Information
- Market Cap$2.72B
- Float91.68%
- Average Daily Volume (1m)7,225,670
- Average Daily Volume (3m)9,420,547
- EPS-$0.36
Company
- Revenue$1.37M
- Rev Growth (1yr)2,941.38%
- Net Income-$67.38M
- Gross Margin49.43%
- EBITDA Margin-7,812.24%
- EBITDA-$68.90M
- EV$2.50B
- EV/Revenue1,817.73
- P/EN/A
- P/S2,147.93
Documents
SEC Filings
Earnings Calls
Factset Street Account